Hemogenyx Pharmaceuticals PLC Director/PDMR Shareholding (6393K)

TIDMHEMO

RNS Number : 6393K

Hemogenyx Pharmaceuticals PLC

11 April 2018

Hemogenyx Pharmaceuticals Plc

("Hemogenyx" or the "Company")

Director / PDMR Shareholding

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that on 9 April 2018 options to subscribe for 18,002,568 ordinary shares of GBP0.01 each in the Company ("Ordinary Shares" and the "Options") were granted to Professor Sir Marc Feldmann, Chairman, Hemogenyx.

The Options were granted as part of a remuneration package. The exercise price of the an Option is GBP0.035 per Option Share. The Option Shares shall vest in 12 quarterly instalments in arrears on and with effect from the first Vesting Date, being 30 June 2018.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1    Details of the person discharging managerial 
       responsibilities / person closely associated 
---  -------------------------------------------------------- 
 a)   Name               Marc Feldmann 
---  -----------------  ------------------------------------- 
 2    Reason for the notification 
---  -------------------------------------------------------- 
 a)   Position/status    Chairman 
---  -----------------  ------------------------------------- 
 b)   Initial            Amendment to prior notifications 
       notification       00038962 
       /Amendment 
---  -----------------  ------------------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  -------------------------------------------------------- 
 a)   Name               Hemogenyx Pharmaceuticals PLC 
---  -----------------  ------------------------------------- 
 b)   LEI                2138008L93GYU5GN6179 
---  -----------------  ------------------------------------- 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  -------------------------------------------------------- 
 a)   Description        Grant of Option 
       of the 
       financial 
       instrument, 
       type of 
       instrument 
       Identification 
       code 
---  -----------------  ------------------------------------- 
 b)   Nature             Acceptance of a stock option granted 
       of the             as part of a remuneration package 
       transaction 
---  -----------------  ------------------------------------- 
 c)   Price(s)            Price   Volume 
       and volume(s)      ------  --------- 
                           0.035   18002568 
                          ------  --------- 
---  -----------------  ------------------------------------- 
 d)   Date of            9 April 2018 
       the transaction 
---  -----------------  ------------------------------------- 
 e)   Place              Outside of a trading venue 
       of the 
       transaction 
---  -----------------  ------------------------------------- 
 

Enquiries:

 
 Hemogenyx Pharmaceuticals Limited                                      www.hemogenyx.com 
 Dr Vladislav Sandler, Chief                                              Via Walbrook PR 
  Executive Officer & Co-Founder 
 Sir Marc Feldmann, Chairman 
 
 Optiva Securities Ltd                                           Tel: [phone] 
 Christian Dennis 
 
 Shard Capital Partners LLP                                      Tel: [phone] 
 Damon Heath, Erik Woolgar 
 
 Peterhouse Corporate Finance                                    Tel: [phone] 
  Limited 
 Lucy Williams/Duncan Vasey 
 
 Walbrook PR (UK Media &                                      Tel: [phone] or 
  Investor Relations)                                            [e-mail] 
 Paul McManus                                                    Mob: [phone] 
 
 US Media enquiries 
 Lowell Goodman                        Tel: [phone] or [e-mail] 
 
 

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York.

HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care.

For more information, visit www.hemogenyx.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBLGDSUBBBGIB

(END) Dow Jones Newswires

April 11, 2018 12:15 ET (16:15 GMT)